AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $214.74M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.12M
Average 0.32M
ACIU Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AC Immune S.A.NASDAQ: ACIU
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of CHF 11.74M fell 26.2% year over year, behind the -17.6% change in trailing-twelve-month research & development. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.
Context
- Research & development amounted to 1579.5% of revenue in FY2025, up 1350.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -26.2% toward the trailing-twelve-month pace of -17.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CHF · from the income statement
- Latest · FY2025
- 56.44M CHF
- Year-over-year change
- -9.8%
- 4-year CAGR
- -2.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56.44M | -9.8% |
| FY2024 | 2024-12-31 | 62.57M | +14.6% |
| FY2023 | 2023-12-31 | 54.61M | -9.5% |
| FY2022 | 2022-12-31 | 60.34M | -3.1% |
| FY2021 | 2021-12-31 | 62.28M | — |
Research & Development vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.6% is the 9th highest of 10, against a peer median of +5.0%.
- Research & development amounts to 1409.6% of revenue for ACIU, versus a peer median of 3625.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M USD | +11.3% | +45.0% | — |
| LTM Mar 2026 | $35.87M USD | +29.3% | +13.9% | — | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding ACIU) | — | +5.0% | +6.9% | 3625.8% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| Weighted Avg Shares | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
| Weighted Avg Shares (Diluted) | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.